 The AlloSure test has been approved for Medicare coverage for clinical use when a physician determines there is a need to assess the probability of allograft rejection in kidney transplant recipients. Accurate and timely detection of allograft rejection and effective treatment are essential for long-term survival of renal transplants. The DART study validated the ability of the non-invasive AlloSure test to measure donor-derived cell-free DNA dd-cfDNA to discriminate active rejection in a renal transplant recipient. Use of the test will inform and may reduce invasive percutaneous renal biopsy procedures among patients with risk of rejection. 